Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients

[1]  P. Galle,et al.  LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC) , 2022, Annals of Oncology.

[2]  P. Gow,et al.  Lenvatinib for the treatment of hepatocellular carcinoma—a real-world multicenter Australian cohort study , 2022, Hepatology International.

[3]  Yu Cheng,et al.  Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH) , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  T. Lui,et al.  Machine learning models in the prediction of 1-year mortality in patients with advanced hepatocellular cancer on immunotherapy: a proof-of-concept study , 2022, Hepatology International.

[5]  A. Zhu,et al.  Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. , 2022, The Lancet. Oncology.

[6]  M. Kudo,et al.  Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. , 2022, NEJM evidence.

[7]  Kang Wang,et al.  Transarterial chemoembolization plus a PD‐1 inhibitor with or without lenvatinib for intermediate‐stage hepatocellular carcinoma , 2022, Hepatology research : the official journal of the Japan Society of Hepatology.

[8]  Zhe Xu,et al.  Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study , 2022, Heliyon.

[9]  Yi‐Hsiang Huang,et al.  Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma , 2022, Cancer Immunology, Immunotherapy.

[10]  Liteng Lin,et al.  Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study , 2022, Frontiers in Immunology.

[11]  J. Cheon,et al.  The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma , 2022, Therapeutic advances in medical oncology.

[12]  M. Kudo,et al.  Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study. , 2020, Journal of hepatology.

[13]  T. Si,et al.  The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study , 2021, Frontiers in Oncology.

[14]  M. Kudo,et al.  Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. , 2021, Journal of hepatology.

[15]  M. Suarez‐Almazor,et al.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Z. Yin,et al.  Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study , 2021, Journal of hepatocellular carcinoma.

[17]  H. Koga,et al.  Lenvatinib versus Sorafenib as first‐line treatment in hepatocellular carcinoma: A multi‐institutional matched case‐control study , 2021, Hepatology research : the official journal of the Japan Society of Hepatology.

[18]  Wei Wei,et al.  Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice , 2021, Cancer Immunology, Immunotherapy.

[19]  H. Koga,et al.  Adverse events as potential predictive factors of activity in advanced hepatocellular carcinoma patients treated with lenvatinib. , 2021, Liver international : official journal of the International Association for the Study of the Liver.

[20]  Yongyi Zeng,et al.  Lenvatinib Plus Camrelizumab versus Lenvatinib Monotherapy as Post-Progression Treatment for Advanced Hepatocellular Carcinoma: A Short-Term Prognostic Study , 2021, Cancer management and research.

[21]  M. Kurosaki,et al.  The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study , 2021, Cancers.

[22]  T. Yau,et al.  Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study , 2021, Liver Cancer.

[23]  Z. Fu,et al.  Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study , 2021, Hepatology International.

[24]  Li Xu,et al.  Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma , 2021, Therapeutic advances in medical oncology.

[25]  J. Zucman‐Rossi,et al.  Hepatocellular carcinoma , 1998, Nature Reviews Disease Primers.

[26]  Minhu Chen,et al.  LBA2 Sintilimab plus bevacizumab biosimilar vs sorafenib as first-line treatment for advanced hepatocellular carcinoma (ORIENT-32)2 , 2020 .

[27]  Jianming Xu,et al.  Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial , 2020, Clinical Cancer Research.

[28]  M. Kudo,et al.  Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  H. Lee,et al.  Effectiveness and Safety of Nivolumab in Child–Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study , 2020, Cancers.

[30]  Yulei N. Wang,et al.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.

[31]  W. Fang,et al.  Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. , 2020, The Lancet. Oncology.

[32]  Chiung‐Yu Chen,et al.  Impact of Immune Checkpoint Inhibitors with or without a Combination of Tyrosine Kinase Inhibitors on Organ-Specific Efficacy and Macrovascular Invasion in Advanced Hepatocellular Carcinoma , 2020, Oncology Research and Treatment.

[33]  M. Kudo,et al.  A phase Ib study of lenvatinib (LEN) plus nivolumab (NIV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 117. , 2020 .

[34]  L. Rimassa,et al.  Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma. , 2019, Cancer treatment reviews.

[35]  M. Omata,et al.  The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting , 2019, Hepatology International.

[36]  E. Thunnissen,et al.  Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[37]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[38]  Yaming Li,et al.  Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition) , 2018, Liver Cancer.

[39]  M. Kudo,et al.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.

[40]  M. Suarez‐Almazor,et al.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  T. Pawlik,et al.  Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group , 2018, Journal of Gastrointestinal Surgery.

[42]  M. Abecassis,et al.  AASLD guidelines for the treatment of hepatocellular carcinoma , 2018, Hepatology.

[43]  I. Endo,et al.  The Tumor Burden Score: A New “Metro-ticket” Prognostic Tool For Colorectal Liver Metastases Based on Tumor Size and Number of Tumors , 2018, Annals of surgery.

[44]  Erich P Huang,et al.  RECIST 1.1-Update and clarification: From the RECIST committee. , 2016, European journal of cancer.

[45]  M. Schmidinger.  Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors , 2013, EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.].

[46]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[47]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .